Literature DB >> 17255808

State of the art of cardiac surgery in patients with congenital heart disease.

Lucio Zannini1, Italo Borini.   

Abstract

During the last 20 years, pediatric cardiac surgery has been characterized by important changes, with reductions in surgical mortality and the achievement of complete repair at an earlier age, thus avoiding multiple procedures and strongly ameliorating the global outcome of these patients. In this review, we describe the actual trends in the surgical treatment of cardiac malformations. We analyze two groups of patients: in the first group (septal defects, tetralogy of Fallot, transposition of the great arteries, aortic stenosis and coarctation) the indications are well established and the goal is represented by a lessening of the surgical trauma and post-operative morbidity, with stable results in the follow-up. In the second group (univentricular heart, pulmonary atresia and intact ventricular septum, double discordance, conduit, hypoplastic left heart syndrome), the lesions are still considered complex and submitted to ongoing experimental and clinical research, in order to improve the post-surgical history of these diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17255808     DOI: 10.2459/01.JCM.0000247427.44204.0d

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  2 in total

1.  Ethical issues in cardiac surgery.

Authors:  Minoo N Kavarana; Robert M Sade
Journal:  Future Cardiol       Date:  2012-05

2.  Transcriptome analysis defines myocardium gene signatures in children with ToF and ASD and reveals disease-specific molecular reprogramming in response to surgery with cardiopulmonary bypass.

Authors:  Federica Raggi; Davide Cangelosi; Pamela Becherini; Fabiola Blengio; Martina Morini; Massimo Acquaviva; Maria Luisa Belli; Giuseppe Panizzon; Giuseppe Cervo; Luigi Varesio; Alessandra Eva; Maria Carla Bosco
Journal:  J Transl Med       Date:  2020-01-10       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.